chr22-36867434-G-A
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The ENST00000248899.11(NCF4):c.314G>A(p.Arg105Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000018 in 1,614,046 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R105W) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000248899.11 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NCF4 | NM_000631.5 | c.314G>A | p.Arg105Gln | missense_variant | 4/10 | ENST00000248899.11 | NP_000622.2 | |
NCF4-AS1 | NR_147197.1 | n.351+2659C>T | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NCF4 | ENST00000248899.11 | c.314G>A | p.Arg105Gln | missense_variant | 4/10 | 1 | NM_000631.5 | ENSP00000248899 | P1 | |
NCF4-AS1 | ENST00000619915.1 | n.349+2659C>T | intron_variant, non_coding_transcript_variant | 4 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152170Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000278 AC: 7AN: 251406Hom.: 0 AF XY: 0.0000441 AC XY: 6AN XY: 135902
GnomAD4 exome AF: 0.0000164 AC: 24AN: 1461876Hom.: 0 Cov.: 32 AF XY: 0.0000179 AC XY: 13AN XY: 727244
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152170Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74330
ClinVar
Submissions by phenotype
Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 3 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 25, 2022 | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects NCF4 function (PMID: 19692703, 29969437). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 30194). This missense change has been observed in individual(s) with chronic granulomatous disease and/or symptoms of chronic granulomatous disease (PMID: 19692703, 29969437). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This variant is present in population databases (rs387906808, gnomAD 0.008%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 105 of the NCF4 protein (p.Arg105Gln). - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 08, 2009 | - - |
Chronic granulomatous disease Pathogenic:1Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 21, 2023 | Variant summary: NCF4 c.314G>A (p.Arg105Gln) results in a conservative amino acid change located in the Phox homology domain (IPR001683) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 251406 control chromosomes. c.314G>A has been reported in the literature in both compound heterozygous and homozygous individuals affected with Chronic Granulomatous Disease (e.g., Matute_2009, vandeGeer_2018), and the variant was shown to segregate with disease in related individuals. These data indicate that the variant is very likely to be associated with disease. At least two publications report experimental evidence evaluating an impact on protein function, finding that the variant results in greatly reduced intracellular NADPH oxidase activity in vitro (e.g., Matute_2009, vandeGeer_2018), although the effect of the variant on NADPH oxidase activity in homozygous patient cells was variable depending on the stimulus (e.g., vandeGeer_2018). The following publications have been ascertained in the context of this evaluation (PMID: 19692703, 29969437). One submitter has reported clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at